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CHAPTER I   
General introduction 
 
1. Bone development and remodeling  
 Two ossification processes occur during the fetal development of the mammalian 
skeletal system, intramembranous ossification and endochondral ossification.  During 
intramembranous ossification, mesenchymal cells differentiate directly into bone and 
form the flat bones of the skull.  In this process, mesenchymal cells first differentiate 
into osteoblasts, which are a type of bone-forming cells.  Next, the osteoblasts begin to 
deposit unmineralized osteoid.  Because calcium phosphate is deposited by osteoblasts, 
the osteoid forms new bone [Bradley et al., 2011]. 
 During endochondral ossification, mesenchymal cells give first rise to a cartilaginous 
frame and are then ossified and replaced, leading to the formation of long bones such as 
limbs (Fig. 1).  In particular, mesenchymal cells differentiate into chondrocytes to 
form a temporary cartilage model.  The cartilage model grows, the chondrocytes 
mature and become hypertrophic, and the growing cartilage model then starts to calcify.  
Chondrocytes undergo apoptosis due to their distance to blood vessels and limited 
uptake of nutrients, etc.  Osteoprogenitor cells and blood vessels from the periosteum 
invade this area; the osteoprogenitor cells proliferate and differentiate into osteoblasts, 
which then begin to lay down a bone matrix.  Osteoclasts, formed from macrophages, 
assist in the removal of cartilage matrix.  In the fetus, primary ossification develops 
first in the diaphysis and a secondary ossification center forms later in the epiphysis 
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[Gerver et al., 2000, Mackie et al., 2008, Gerver et al., 2000].  
 During fetal and postnatal life, continuous bone remodeling occurs in a coordinated 
action involving bone-forming osteoblasts and bone-resorbing osteoclasts to maintain 
the bone mass.  
 
 
Fig.1 Endochondral ossification 
 
2. Role of estrogen in osteoporosis 
 Osteoporosis is a disease caused by low bone mass due to increased osteoclast 
activity and/or decreased osteoblast activity.  This disease is thought to be due to a 
multi-factorial condition such as low calcium intake, low vitamin D levels [Gennari, 
2001], and low sex hormone levels [Albright et al., 1940].  In particular, 
postmenopausal osteoporosis is caused primarily by estrogen deficiency.  
 With regard to its effects on bone resorption, estrogen has been shown to induce 
apoptosis in bone-resorbing osteoclasts [Kousteni et al., 2002], and estrogen receptor 
(ER) knockout mice have an increased total number of osteoclasts due to the absence of 
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estrogen-induced osteoclast apoptosis [Parikka et al., 2005].  ER! expression in 
osteoclasts is required for apoptosis via estrogen and expression of the Fas ligand in 
bones leads to estrogen-induced apoptosis [Nakamura et al., 2007].  Moreover, 
estrogen affects osteoclast survival through upregulation of the Fas ligand in osteoblasts 
[Krum et al., 2008].  
 During bone formation, estrogen increases osteoblast proliferation and decreases 
osteoblast and osteocyte apoptosis [Kousteni et al., 2002].  However, the detailed 
molecular mechanisms, e.g., identification of the peptide/protein factors or enzymes 
associated with osteoblast differentiation and the signal network—from the stimulation 
by estrogen to the expression of genes participating in bone differentiation—have not 
been clarified yet.   
 
3. Characterization of subtilisin-like proprotein convertases (SPCs) 
 Many bioactive proteins such as peptide hormones and growth factors, including 
bone morphogenetic proteins (BMPs), are biosynthesized as inactive precursor proteins 
that convert into the mature form through partial cleavage by specific processing 
proteases at the C-terminal tail of basic amino acids with the recognition motif RXXR; 
the RXK/RR motifs provide an optimum processing site [Molloy et al., 1992] (Table 1).  
The partial cleavage process is required for the biosynthesis of bioactive proteins.  
 Homologues of kexin, which is a processing protease first isolated from yeast, were 
subsequently isolated in mammals in the following order: Furin [Fuller et al., 1989], 
PC1/PC3 and PC2 [Smeekens et al., 1990], PACE4 [Kiefer et al., 1991], PC4 
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[Nakayama et al., 1992], PC5/PC6 [Nakagawa et al., 1993], and PC7/PC8 [Bruzzaniti 
et al., 1996].  These proteases are regarded as subtilisin-like proprotein convertases 
(SPCs) because they are serine proteases with Ca
2+
 dependency and their catalytic 
region is similar to that of subtilisin (Fig. 2). 
 
 
Fig.2 Domain structure of subtilisin-like proprotein convertases 
Sig: signal peptide, Pro: propeptide, SCD: subtilisin-like catalytic domain 
Homo B: homologous domain B, CRR: cysteine-rich region, TM: transmembrane domain 
 
 The N-terminal domain is conserved in all family members, whereas great diversity 
is found in the C-terminal domains of the different SPCs.  These proteases become 
active through autocatalytic cleavage of an N-terminal propeptide.  The propeptide 
domain functions as chaperone for the proenzyme [Nakayama, 1997], and the Homo B 
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domain, as well as the catalytic domain, are required for autocatalytic activation 
[Takahashi et al., 1995].  PACE4 and PC5/6 as extracellular matrix-bound enzymes 
have a heparin-binding region in the cysteine-rich region [Tsuji et al., 2003].  PACE4 
is conserved in humans and mice, and the knockout mouse of this gene has been 
previously shown to have bone-morphogenesis defects [Constam et al., 2000] (Table 2). 
 
Table.1: Sequence around the cleavage site of potential precursor proteins in 
 mouse bones  
 
Arrows indicate the predicted cleavage sites. 
 
Table.2: Comparison of human and mouse PACE4  
Chromosomal 
localization 
Identity Gene 
length 
Exon 
number 
Tissue 
distribution 
Knockout mouse 
human mouse 
15q26 7 
86% >250 kb 22 nervous 
system, heart, 
liver, bone 
75% viable phenotype 
with bone morphogenesis 
defects, cyclopia 
Precursor proteins Sequences at the cleavage site 
Osteocalcin 
ChM-1 
PTHrP 
FGF23 
BMP family 
BMP1 
BMP2 
BMP3 
BMP4 
BMP5 
BMP6 
BMP7 
BMP8 
BMP9 
BMP10 
BMP15 
VNRLRR"YL 
IQRERR"EV 
SRRLKR"AV 
PRRHTR"SA 
 
RPRSRR"AA 
HKREKR"GA 
KKARRK"GW 
RRRAKR"SP 
LLRSVR"AA 
HVRTTR"SA 
HLRSIR"ST 
PVRAPR"AA 
LARRKR"ST 
SARIRR"NA 
LMRSVR"GA 
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CHAPTER II 
Estrogen stimuli promote osteoblastic differentiation via 
PACE4 in MC3T3-E1 cells 
 
1. Introduction 
 Bone mass is constantly maintained through the so-called bone remodeling process, 
which consists of bone formation by osteoblasts and bone resorption by osteoclasts.  
However, bone mass decreases with age, especially in postmenopausal women with low 
blood estrogen levels [Albright et al., 1940].  These women are predisposed to 
osteoporosis due to the collapse of the balance between bone formation and resorption, 
which results in net bone resorption [Jasani et al., 1965; Riggs et al., 2002]. Because 
osteoporosis-related fractures are very problematic for elderly people [Kanis et al., 
2004], endochondral ossification is required for fracture healing and where a cartilage 
frame formed by chondrocytes is replaced with bone, estrogen replacement therapies for 
the treatment and prevention of osteoporosis are particularly important [Riggs et al., 
2002; Scammell et al., 1996].  For example, the soybean isoflavone daidzein (Diz) is a 
phytoestrogen with estrogenic activity and its intake is effective for the maintenance of 
bone mass in postmenopausal women [Ma et al., 2008].  Moreover, equol (Eq), which 
is a metabolite of Diz, has been shown to have greater estrogenic activity than Diz. 
[Setchell et al., 2002].   
 7 
 It has been reported that estrogen induces apoptosis in osteoclasts [Kameda et al., 
1997], and the number of osteoclasts has been found to increase in ovariectomized mice 
[Kousteni et al., 2002].  While estrogen suppresses bone resorption, it was also shown 
to attenuate apoptosis through activation of the Src/Shc/ERK signaling pathway in 
osteoblasts [Kousteni et al., 2001].  Furthermore, estrogen stimuli, including 
phytoestrogens such as Diz, enhanced bone mineralization of a murine osteoblastic cell 
line [Kanno et al., 2004].  Thus, understanding the mechanism of how estrogen stimuli 
facilitate bone formation is important to develop treatment and prevention therapies for 
osteoporosis.  However, the detailed molecular mechanisms underlying bone 
formation triggered by estrogen stimuli have not been clarified yet.  It is well known 
that BMPs are highly linked with ossification and bone formation via Smad signaling.  
It is thought that several factors related to ossification, including BMPs, have to 
undergo proteolytic processing to convert to the active form; furthermore, the SPC 
family, which are serine endoproteases, play key roles in activating the precursors of 
BMPs with a consensus cleavage motif for SPCs [Constam et al., 1999].  Recently, it 
has been reported that an SPC regulates the hypertrophic conversion of murine 
chondrocytes through activation of BMP6 [Yuasa et al., 2012].  Therefore, in the 
present study, I investigated the mechanism underlying the effect of estrogen stimuli on 
osteoblasts, with focus on the role of SPCs. 
 
2. Materials and methods 
2-1. Cell culture 
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 ATDC5, a mouse chondrogenic cell line derived from embryonal carcinoma cells, 
was provided by Drs. Yuji Hiraki and Chisa Shukunami of Kyoto University [Yuasa et 
al., 2012].  Cells were cultured in growth medium consisting of Dulbecco’s modified 
Eagle’s medium:Ham’s F12 (1:1) containing 5% fetal bovine serum (FBS) (inactivated 
by treatment at 56°C), 10 µg/mL transferrin, 30 nM sodium selenite, 100 U/mL 
penicillin G potassium, and 100 µg (titer)/mL streptomycin sulfate.  MC3T3-E1, an 
osteoblast cell line from C57BL/6 mouse calvaria, was obtained from the RIKEN Cell 
Bank (No. RCB1126).  MC3T3-E1 cells were cultured in Minimum Essential Medium 
Alpha (Wako) containing 10% FBS, 100 U/mL penicillin G potassium, and 100 µg 
(titer)/mL streptomycin sulfate.  Cell culture of both cell lines was carried out in a 5% 
CO2-air incubator at 37°C. 
 
2-2. Differentiation culture with estrogen stimuli 
 ATDC5 cells and MC3T3-E1 cells were seeded at 1 # 10
4
 cells/cm
2
 into wells of 
24-well culture plates containing 0.5 mL/well or in 35-mm culture dishes containing 2 
mL/dish of the respective growth medium.  When the cells reached confluence, the 
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medium was replaced with the same volume of differentiation medium containing FBS 
or charcoal-dextran-treated FBS (CD-FBS).  CD-FBS was prepared by treatment of 
FBS with dextran-coated charcoal (Sigma) to reduce the amount of endogenous 
estrogen, as described previously [Kanno et al., 2004].  Briefly, 10 g of dextran-coated 
charcoal and 200 mL of FBS were mixed at 37°C for 1 h with constant stirring.  The 
treated FBS was centrifuged at 2500 # g for 20 min, and the supernatant was sterilized 
by filtration through a 0.2-µm filter.  Differentiation medium for ATDC5 cells was 
prepared by addition of 10 µg/mL insulin and that for MC3T3-E1 cells was prepared by 
addition of 5 mM $-glycerophosphate and 0.2 mM L-ascorbic acid to the growth 
medium.  Estrogenic agents such as 17$-estradiol (E2) and the soybean isoflavones 
Diz and the S-form of Eq were dissolved in dimethyl sulfoxide and added to the 
differentiation medium containing CD-FBS.  To evaluate the dependency of the effect 
of estrogenic agents on the estrogen receptor (ER), the ER inhibitor fulvestrant (Sigma) 
was added to the differentiation medium at 1 µM and incubated as described above.   
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2-3. Alcian blue staining and alizarin red S staining 
 After incubation in the differentiation medium for the designated time, the 
differentiation of ATDC5 cells and MC3T3-E1 cells was monitored by alcian blue 
staining and alizarin red S staining, respectively.  ATDC5 samples were washed three 
times with phosphate-buffered saline and then fixed with 99% methanol at room 
temperature.  After 20 min, the cells were stained with alcian blue for 1 day and then 
washed with dH2O.  MC3T3-E1 samples were washed three times with 
phosphate-buffered saline and then fixed with ice-cold 70% ethanol for 1 h on ice.  
Subsequently, the cells were washed with distilled H2O and stained with alizarin red S 
for 20 min at room temperature.  To quantify the relative differentiation, their 
absorbance at 520 nm was measured in a spectrometer (Tecan Infinite M200) after 
several washes with distilled H2O. 
 
2-4. Reverse transcription-polymerase chain reaction (RT-PCR) and quantitative 
real-time PCR (qRT-PCR) 
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 Total RNA was extracted from MC3T3-E1 cells during the time course using the 
Qiagen RNeasy mini kit (Qiagen).  Subsequently, cDNA was synthesized by reverse 
transcription using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems).  Both steps were performed according to the manufacturer’s instructions.  
RT-PCR performed using 1 µL of template solution containing cDNA equivalent to 100 
ng mRNA was performed for 15, 22, and 25 cycles for glyceraldehyde-3-phosphate 
dehydrogenase (for the data in Figs. 6 and 7) and all other genes, respectively, by using 
a gene-specific primer set: an initial step at 95°C for 2 min, followed by 95°C for 1 min, 
50°C or 53°C for 1 min, and 72°C for 1 min (Table 3).  Each primer set corresponding 
to the target genes was designed to amplify a partial region of the entire cDNA (Fig. 3).  
qRT-PCRs were performed using the Power SYBR Green PCR Master Mix (Applied 
Biosystems) according to the manufacturer’s protocol with primer sets for 
glyceraldehyde-3-phosphate dehydrogenase, ER!, ER$, and PACE4 (Table 3); those 
for furin [Hwang et al., 2006] and PC7 [Marchesi et al., 2011] were performed using 
the ABI Prism 7000 Sequence Detection System. 
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Table 3: Primer sets for RT-PCR/qRT-PCR 
Gene Primer Sequence   
 ER$ Fw: 5’-cagctcaacagcgtgtcgccta-3’ 
  Rev: 5’-gtttcctttctcgttactgctgg-3’ 
 ER% Fw: 5’-atggccaacttctggacacctc-3’ 
  Rev!5’-cttggcgcttggactagtaa-3’ 
 GR Fw!5’-acctcaataggtcgaccagc-3’ 
  Rev!5’-cccgccaaaggagaaagcaag-3’ 
 SOX5 Fw!5’-cttggtgctgccgtgtctcctacc-3’ 
  Rev!5’-atagcctattgtgctaactcttgc-3’ 
 SOX9 Fw: 5’-gcaaagttgatctgaagcgagagg-3’ 
  Rev!5’-ccagtgtaggtgacctggccgt-3’ 
 RUNX2 Fw!5’-tcgcctcagtgatttagggcgca-3’ 
  Rev!5’-gtggcagtgtcatcatctgaaatac-3’ 
 Osterix Fw!5’-tccctacccagcgccccacctct-3’ 
  Rev!5’-ctgtgaatgggcttcttcctcagc-3’ 
 Osteopontin Fw!5’-gatgaatctgacgaatctcacc-3’ 
  Rev!5’-ctcagaagctgggcaacagggat-3’ 
 Osteocalcin Fw!5’-ccctgagtctgacaaagccttca-3’ 
  Rev!5’-tactggtctgatagctcgtc-3’ 
 FGF23 Fw!5’-gagaatggctatgacgtctacttg-3’ 
  Rev!5’-gctcgcgagagcaggataca-3’ 
 FGFR1 Fw!5’-gttcaagcagttggtggaagtcc-3’ 
  Rev!5’-cagcgccgtttgagtccactg-3’ 
 FGFR2 Fw!5’-gaggaatacttggatctcacccag-3’ 
  Rev!5’-aacactgccgtttatgtgtggatac-3’ 
 FGFR3 Fw!5’-cgcatcctcactgtgacatcaacc-3’ 
  Rev!5’-cgttactgggtggacctgggg-3’ 
 Col-I Fw!5’-gagaagtctcaagatggtggc-3’ 
  Rev!5’-gcggggtcggagccctcgctt-3’ 
 Col-II Fw!5’-ccaccccgagtggaagagcggaga-3’ 
  Rev!5’-cagccatccttcagggcagtgtat-3’ 
 Col-X Fw!5’-ggcagcagcattacgacccaag-3’ 
  Rev!5’-gcattgggcaattggagccatacc-3’ 
 ALP Fw!5’-cactcgggtgaaccacgccaca-3’ 
  Rev!5’-ctgatgagatccagaccatctagcc-3’ 
Gene Primer Sequence 
 BMP1 Fw!5’-gccgaggaaggctatggcgtgga-3’ 
  Rev!5’-gcttgtgtaccgcaggtggaagc-3’ 
 BMP2 Fw!5’-ccaggagcgcccgccccagacc-3’ 
  Rev!5’-tggttggtgtgtccctgtgt-3’ 
 BMP3 Fw!5’-ggtcatctgtctgtagatgtgg-3’ 
  Rev!5’-caagggcagcaagatcccagtag-3’ 
 BMP4 Fw!5’-cgctggacccgggaaaagcaac-3’ 
  Rev!5’-gcgacggcagttcttattcttctt-3’ 
 BMP5 Fw!5’-ctcatcagaggaggcattacaaaga-3’ 
  Rev!5’-ctgcacagagctgtaagcccaaa -3’ 
 BMP6 Fw!5’-ggcggtgcgtccccactgacta-3’ 
  Rev!5’-gccccatgttgtgctgcggtgt-3’ 
 BMP15 Fw!5’-catcaaaccaggtagcatacg-3’ 
  Rev!5’-gagtagcaagaaggcaacatccaag-3’ 
 ChM-1 Fw!5’-gaactcgctgatttgggtggccgt-3’ 
  Rev!5’-ctggtggtaaggattgtcagggt-3’ 
 PTHrP Fw!5’-gatcgcggagatccacacagcc-3’ 
  Rev!5’-cgcttctttttctcctgttctc-3’ 
 furin Fw!5’-gagaatgatgtggagatcatccgtg-3’ 
  Rev!5’-tctgagtccgatgggcactcct-3’ 
 PC1 Fw!5’-cctcggaggtcccgaagaagc-3’ 
  Rev!5’-gtgtgattccactccaagccatca-3’ 
 PC2 Fw!5’-acctggagcacgtccaagctgtc-3’ 
  Rev!5’-ccgtgaagcatcagggtccattc-3’ 
 PC4 Fw!5’-cactcactactgggatgagga-3’ 
  Rev!5’-cagctggcctgtccttcggt-3’ 
 PC6 Fw!5’-gtcttcagggatcccgctgttcg-3’ 
  Rev!5’-gaatcctggcccattgcatgtc-3’ 
 PC7 Fw!5’-ctggatggagtggattcagagc -3’ 
  Rev!5’-agcaaatctgcccgctcttccc -3’ 
 PACE4 Fw!5’-accgggtacctacttcgattca-3’ 
  Rev!5’-tcgcagctcaggcagttctc-3’ 
 GAPDH Fw!5’-gggtggagccaaacgggtc-3’ 
  Rev!5’-ggagttgctgttgaagtcgca-3’ 
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2-5. PACE4 knockdown in MC3T3-E1 cells 
 MC3T3-E1 cells were grown in 35-mm dishes to 50% confluence and then 
transfected with 2 µg of a PACE4 or green fluorescent protein (GFP) 
shRNA-expressing vector [Yuasa et al., 2009] using the FuGENE
®
 6 Transfection 
Reagent (Roche) according to the manufacturer’s protocol.  PACE4 and GFP 
shRNA-expressing vectors were generated by ligation of the sequence corresponding to 
shRNA against mPACE4 (G
429
CGAAGTGACTCTCTTTATT
448
) and the GFP target 
sequence (as recommended by the manufacturer) into the vector pSilencer 3.1-H1 neo 
(Ambion).  After 24 h of cultivation, the used medium was replaced with fresh growth 
medium containing 400 µg/mL G418 (Nacalai Tesque).  This selection step was 
continued for 2 weeks; the medium was changed every 3 days.  The cells were then 
applied to the cell differentiation assay and subjected to qRT-PCR. 
 
3. Results 
3-1. Differentiation of MC3T3-E1 cells induced by estrogen stimuli 
 To confirm the pharmacological effects of estrogen stimuli on ossification and to 
investigate their effect on the prevention of osteoporosis, the ATDC5 chondrogenic cell 
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line and the MC3T3-E1 osteoblastic cell line were used as typical model cells 
responsible for bone formation.  Cells were cultured with the endogenous estrogen E2 
or the phytoestrogen Diz and the S-form of Eq in differentiation medium containing 
CD-FBS.  First, CD-FBS was prepared by CD treatment to reduce the amount of 
endogenous estrogens.  The E2 concentration was less than the detection limit (<10 
pg/mL); CD-FBS was used for cell cultivation to mimic the estrogen-poor condition 
observed in postmenopausal women.  E2 is the predominant estrogen, and Diz is a 
typical soybean isoflavone with phytoestrogen activity.  Diz is metabolized to Eq by 
intestinal bacteria such as Lactococcus garvieae [Uchiyama et al., 2004]; Eq is known 
to be a potent soybean isoflavone.  Because the structures of Diz and Eq are similar to 
that of E2 (Fig. 4), these compounds are able to bind to both ER! and ER$ [Usui et al., 
2006].  As shown in Figure 5, the presence of estrogen stimuli did not significantly 
affect chondrogenic differentiation of ATDC5 cells (Fig. 5a).  On the other hand, in 
MC3T3-E1 cells, the cultivation period-dependent mineralization was significantly 
decreased in culture medium containing CD-FBS compared to that containing normal 
FBS.  Moreover, the mineralization ability was restored by treatment with Eq, Diz, or 
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E2, even on culture in a medium containing CD-FBS (Fig. 5b).  The differentiation of 
MC3T3-E1 cells by these estrogen stimuli was dose-dependent, and Eq was 
approximately 10-fold more effective than Diz (Fig. 5c).  Furthermore, these inductive 
effects were inhibited by addition of the selective ER downregulator fulvestrant, which 
could bind to both ER! and ER$ [Tremblay et al., 1997, Paige et al., 1999] (Fig. 5d).  
As expected, these results suggest that the induction effect of isoflavones is dependent 
on the ER.  
 
 
Fig. 4: Chemical structures of estradiol, daidzein, and equol. 
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Fig. 5: Effects of the estrogenic agents equol, daidzein, and estradiol on the 
differentiation of ATDC5 cells and MC3T3-E1 cells. 
Both cell lines were cultured in the respective differentiation medium containing 
charcoal-dextran-treated fetal bovine serum (CD-FBS) with no estrogen stimulus, 10
-5
 M equol 
(Eq), 10
-5
 M daidzein (Diz), or 10
-9
 M estradiol (E2).  After each cultivation period, the 
differentiation of ATDC5 and MC3T3-E1 cells was detected by alcian blue staining (a) and 
alizarin red S staining (b), respectively.  c To investigate the dose response of the estrogen 
stimuli in MC3T3-E1 cells, the cells were cultured in differentiation medium containing FBS 
only, CD-FBS only, CD-FBS with Eq (10
-7
, 10
-6
, or 10
-5
 M), CD-FBS with Diz (10
-7
, 10
-6
, or 
10
-5
 M), or CD-FBS with E2 (10
-11
, 10
-10
, or 10
-9
 M) (upper picture).  Subsequently, 
MC3T3-E1 cells were stained by alizarin red S to confirm mineralization, and the staining 
intensity was quantified by measuring the absorbance at 520 nm (n = 2) (lower graph).  d To 
investigate the effect of fulvestrant (Ful) on the differentiation induced by estrogenic agents, 
MC3T3-E1 cells were co-cultured for 4 weeks with each estrogenic agent (10
-7
 M Eq, 10
-7
 M 
Diz, and 10
-11
 M E2) in differentiation medium containing CD-FBS and 10
-6
 M Ful. 
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3-2. Effect of estrogen stimuli on the expression patterns of bone-related genes in 
MC3T3-E1 cells 
 The molecular effects of estrogen stimuli on osteoblast differentiation were 
investigated by analyzing the expression patterns of bone-related genes in MC3T3-E1 
cells.  Bone-related genes include the following factors: ER and glucocorticoid 
receptors responsible for steroid hormone signaling (ER!, ER$, and GR), collagens that 
are a type of differentiation markers of osteoblasts (type I collagen [Col-I], type II 
collagen [Col-II], and type X collagen [Col-X]), transcription factors related to 
mesenchymal stem cell differentiation (SOX5, SOX9, RUNX2, and osterix), 
extracellular matrix proteins (osteopontin and osteocalcin), fibroblast growth factors 
(FGFR1, FGFR2, FGFR3, and FGF23), factors associated with the differentiation of 
osteoclasts (PTHrP, RANKL, and osteoprotegerin), BMPs (BMP1, BMP2, BMP3, 
BMP4, BMP5, BMP6, BMP7, and BMP15), SPCs (furin, PC1, PC2, PC4, PC6, PACE4, 
and PC7), chondromodulin-1 (ChM-1), which promotes chondrocyte differentiation, 
and the bone differentiation marker alkaline phosphatase (ALP).  Transcription levels 
of several genes changed during the differentiation of MC3T3-E1 cells (Figs. 6a-6d).  
For example, the transcription of Col-II decreased, while those of osteocalcin and 
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BMP4 increased as differentiation progressed.  Most genes were not affected by 
estrogen stimuli.  However, I found that the transcription of PACE4 was upregulated 
by estrogen stimuli as differentiation progressed (Fig. 6e).  Other SPCs such as furin 
and PC7 were also expressed in MC3T3-E1 cells, but their expression did not depend 
on estrogen stimuli.  No significant expression of other SPCs was observed.  
Subsequently, I quantitatively estimated the relative transcription level of the PACE4 
gene in a time course study in the presence and absence of estrogen stimuli (Fig. 7a).  
As shown in Figure 7a, PACE4 gene transcription was significantly induced by Diz, Eq, 
and E2 at the late stage of osteoblast differentiation.  Interestingly, sequencing of the 
amplicon of the PACE4 gene fragment revealed that the PACE4 isoform expressed in 
MC3T3-E1 cells was PACE4A-II, the expression of which has been confirmed in 
placenta and HepG2 cells [Mori et al., 1999] (GenBank Acc. No. NM_138319.2).  
Moreover, because I found that the ER! mRNA levels tended to increase in response to 
the lack of estrogen stimuli (Fig. 6e), I quantitatively analyzed the mRNA levels of ER! 
and ER$ (Figs. 7b and 7c).  ER! expression was upregulated over time in the absence 
of estrogen stimuli.  However, in medium containing endogenous estrogen or in the 
 21 
presence of the exogenous estrogens E2, Eq, and Diz, its expression level in MC3T3-E1 
cells was unchanged or decreased as osteoblast differentiation progressed.  However, 
the mRNA level of ER$ did not show such a response to the presence of estrogens. 
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Fig. 6: Time course of the transcriptional expression patterns of bone-related 
genes. 
MC3T3-E1 cells were cultured in differentiation medium containing charcoal-dextran-treated 
fetal bovine serum with no estrogen stimulus, 10
-5
 M equol (Eq), 10
-5
 M daidzein (Diz), or 
10
-9
 M estradiol (E2).  Over a period of 4 weeks, total RNA was isolated from cultured cells 
once a week, and the mRNA levels of bone-related genes were analyzed by reverse 
transcription-polymerase chain reaction: a 1 week; b 2 weeks; c 3 weeks; and d 4 weeks.  
 e The results of two genes that showed remarkable changes depending on the estrogen stimuli 
and those of the estrogen receptor $ (ER$) gene (for comparison) are shown separately.  The 
endogenous housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was 
used as control. 
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Fig. 7: Time course of the expression patterns of PACE4, ER!, and ER" in the 
presence or absence of estrogen stimuli. 
MC3T3-E1 cells were cultured in differentiation medium containing fetal bovine serum (FBS) 
only, charcoal-dextran-treated FBS (CD-FBS) only, CD-FBS with 10
-5
 M equol (Eq), CD-FBS 
with 10
-5
 M daidzein (Diz), or CD-FBS with 10
-9
 M estradiol (E2) for 4 weeks.  The 
transcriptional levels of PACE4 (a) (n = 3) and those of estrogen receptor ! (ER!) (b) and ER$ 
(c) were analyzed by reverse transcription-polymerase chain reaction (RT-PCR) and 
quantitative RT-PCR(n = 2) using cDNA prepared at each indicated time point as templates 
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3-3. Requirement of PACE4 for the differentiation of MC3T3-E1 cells 
 PACE4 is a member of the SPCs, which are required for the maturation/activation 
of bone formation factors such as BMPs [Constam et al., 1999, Akamatsu et al., 1999] 
and osteocalcin [Viegas et al., 2013].  To examine whether the expression of PACE4 is 
only the result of osteoblast differentiation or if it plays an important role during 
differentiation and mineralization, I prepared PACE4-knockdown MC3T3-E1 cells.  
The PACE4- or GFP-specific shRNA expression vector was transfected into 
MC3T3-E1 cells, and selection culture with G418 was carried out for 2 weeks.  
GFP-specific shRNA-expressing MC3T3-E1 cells were used as mock cells.  
G418-resistant cells were cultured in differentiation medium containing FBS, CD-FBS, 
CD-FBS with Eq, CD-FBS with Diz, or CD-FBS with E2 until the late differentiation 
stage.  Then, we quantitatively monitored the transcriptional levels of PACE4, furin, 
and PC7 expression in MC3T3-E1 cells cultured in differentiation medium containing 
FBS (Fig. 8a).  The mRNA level of PACE4 was clearly downregulated in PACE4 
shRNA-expressing MC3T3-E1 cells compared to that in mock cells.  The shRNA 
targeting PACE4 used in this experiment was confirmed to be specific for the mRNA of 
the PACE4 gene because PACE4-specific shRNA caused almost no significant 
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suppression of the transcription of furin or PC7.  In the mineralization assay of 
PACE4-knockdown cells and mock cells cultured in the presence or absence of estrogen 
stimuli using alizarin red S staining, PACE4-knockdown cells showed a strong decrease 
in mineralization, even in the presence of estrogen stimuli, whereas the differentiation 
of mock cells had significantly progressed in the presence of FBS or the estrogen 
stimuli Eq, Diz, and E2 with CD-FBS at the late differentiation stage, similar to normal 
MC3T3-E1 cells (Fig. 8b).  This result strongly suggests that PACE4 is required for 
the differentiation of osteoblasts. 
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Fig. 8: Effect of PACE4 knockdown on the mineralization of MC3T3-E1 cells. 
MC3T3-E1 cells transfected with the PACE4-specific short hairpin RNA (shRNA) expression 
vector (shPACE4) or the green fluorescent protein (GFP)-specific shRNA expression vector 
(shC) were selected by cultivation in the presence of G418 for 2 weeks.  Cells were then 
cultured in differentiation medium containing fetal bovine serum (FBS), 
charcoal-dextran-treated FBS (CD-FBS), CD-FBS with equol (Eq) (10
-7
, 10
-5
 M), CD-FBS with 
daidzein (Diz) (10
-7
, 10
-5
 M), or CD-FBS with estradiol (E2) (10
-11
, 10
-9
 M) until the late 
differentiation stage, respectively.  a The expression levels of subtilisin-like proprotein 
convertases such as PACE4, furin, and PC7 in shC and shPACE4 after 4 weeks of cultivation in 
differentiation medium containing FBS were analyzed by quantitative reverse 
transcription-polymerase chain reaction (n = 3) to determine whether shPACE4 was specific to 
PACE4.  b To investigate the requirement of PACE4 expression for cell differentiation, 
transfected cells were stained with alizarin red S (upper picture) after 3 weeks of cultivation in 
differentiation medium containing FBS, CD-FBS, or CD-FBS with each estrogenic agent, and 
the mineralization level was quantified by measuring the absorbance at 520 nm (n = 3) (lower 
graph). 
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4. Conclusion 
 With aging and decreases in the blood estrogen level, osteoporosis can adversely 
affect the quality of life of elderly people, especially postmenopausal women.  
Estrogen replacement therapy is regarded as an effective treatment for preventing 
osteoporosis.  Moreover, the intake of soybeans containing isoflavones, which are 
phytoestrogens that mimic the action of estrogen, is an effective and attractive way to 
further increase endogenous estrogen levels.  Recently, it has been suggested that 
people in whom Diz is metabolized to Eq by intestinal bacterial flora have better bone 
health owing to the maintenance of bone mass, compared to those in whom intestinal 
bacteria do not produce Eq [Wu et al., 2007].  It is well known that most stages of the 
bone formation process depend on endochondral ossification, where the cartilage 
formed by chondrocytes is replaced with bone derived from osteoblasts.  Therefore, 
we investigated which step of the cell differentiation process is regulated by estrogen 
stimuli, i.e., the induction efficiency of cell differentiation by estrogen stimuli was 
compared between ATDC5 and MC3T3-E1 cells.  As shown in Figures 5a and 5b, 
compared to ATDC5 cells, differentiation of MC3T3-E1 cells was clearly under the 
control of estrogen stimuli, i.e., it was induced by E2 and the phytoestrogens Diz and 
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Eq.  I also investigated the dose-dependent effect of E2 and phytoestrogens on the 
differentiation of MC3T3-E1 cells.  As shown in Figures 5c and 5d, Eq facilitated 
osteoblast differentiation more effectively than Diz via the ER; however, E2 was a 
significantly stronger inducer than these phytoestrogens.  Among the different ERs, 
ER! has been reported to have a role in osteoblast mechanotransduction via activation 
of the $-catenin-mediated Wnt signaling pathway, which is involved in bone formation 
[Armstrong et al., 2007].  As shown in Figure 6, the mRNA level of ER!  was higher 
than that of ER$.   Furthermore, the expression of ER! was more sensitive to the 
absence of estrogen stimuli, i.e., in the absence of estrogen stimuli, ER! levels 
increased over time in MC3T3-E1 cells cultured in medium containing CD-FBS.  
However, the expression of ER$ was not affected by the presence of estrogen stimuli 
(Figs. 7b and 7c).  Thus, my experimental results also suggest that ER! is the primary 
receptor responsible for estrogen stimuli to facilitate bone formation.  Moreover, 
although both Diz and Eq showed higher affinity to ER$ than to ER!, the binding 
affinities of Eq to both ER! and ER$ were higher than those of Diz [Usui et al., 2006, 
Muthyala et al., 2003, Morito et al., 2001].  These findings may provide an 
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explanation for the results shown in Figure 5c, which shows that Eq is more effective 
than Diz in inducing differentiation of MC3T3-E1 cells.  
 I also investigated the time course of the expression of bone formation-related 
genes in MC3T3-E1 cells by RT-PCR.  The expression levels of several genes such as 
Bmp4 and osteocalcin increased during cell differentiation, but their expression was not 
responsive to estrogen stimuli.  Of these genes, the expression of PACE4, a member of 
the SPC family, changed considerably in response to estrogen stimuli and increased as 
osteoblast differentiation progressed; however, the transcription of other SPCs such as 
furin and PC7 was independent of estrogen stimuli (Fig. 6 and Fig. 7a).  Unlike furin, 
which is a ubiquitously and constitutively expressed membrane-bound SPC, PACE4 is 
localized in the extracellular matrix and its expression levels change markedly during 
development and differentiation [Yuasa et al., 2009].  SPCs can cleave the precursors 
of BMPs, which regulate skeletogenesis, to convert them to the active forms.  For 
example, furin and/or PC6 proteolytically activate BMP4 [Cui et al., 1998] and PACE4 
activates BMP6 [Yuasa et al., 2012].  In addition, it has been reported that the 
transcription of BMP2 is increased by treatment with E2 after 24 h in mouse 
 30 
mesenchymal stem cells that differentiated into osteoblasts [Zhou et al., 2003]; 
furthermore, furin has been shown to convert proBMP2 to mature BMP2 [Felin et al., 
2010].  In the present study, mRNA expression of BMP2 and BMP6 in MC3T3-E1 
cells was confirmed at trace levels; however, their expression levels were not linked 
with the cell differentiation induced by estrogen stimuli.  Although the mRNA 
expression of BMP4 significantly increased as differentiation progressed, the increase 
was not a response to estrogen stimuli.  Therefore, it is difficult to explain the 
correlation between osteoblast differentiation and estrogen stimuli only on the basis of 
the SPC/BMP substrate relationship identified to date.  As shown in Figures 6 and 7a, 
among the SPCs expressed in MC3T3-E1 cells, only the increase in the expression of 
PACE4 can be linked to osteoblast differentiation.  In addition, knockdown of PACE4 
resulted in delayed osteoblast differentiation (Fig. 8b).  PACE4 plays a key role in 
chondrogenic cell differentiation via processing of BMP6 [Yuasa et al., 2012]; therefore, 
it is reasonable that PACE4 also regulates the differentiation of osteoblasts related to 
bone formation.  However, the differentiation of chondrogenic cells was not affected 
by estrogen stimuli, as shown in Figure 5a.  Moreover, the PACE4 isoform expressed 
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in osteoblastic cells was isoform A-II, which is a rare isoform of PACE4; to date, it has 
been confirmed to be present in HepG2 cells and the placenta.  Therefore, the 
expression of PACE4 seems to be regulated by different independent systems in 
chondrogenic cells and osteoblastic cells, and PACE4 may control osteoblast 
differentiation via combinations of substrate(s) that are different from those in 
chondrogenic cells.  After binding of the estrogenic ligand to its receptor to regulate 
the expression of target genes, the ER-ligand complex translocates to the nucleus, where 
it activates transcription directly by binding to the response element or indirectly via 
other DNA-binding proteins [Björnström et al., 2005].  The ER can bind to DNA in 
less than 1 h after ligand binding [Métivier et al., 2005].  However, it took several 
weeks to show a significant increase in the transcription of PACE4 in response to 
estrogen stimuli; furthermore, there are no typical ER response elements in the upstream 
region of the PACE4 gene.  Therefore, it is thought that PACE4 may be indirectly 
regulated by some other gene(s) that is directly targeted by estrogen stimuli, or by 
post-transcriptional regulation, e.g., mRNA stabilization/destabilization, governed by 
RNA-binding proteins [Lal et al., 2004].  Among the SPCs, a significant correlation 
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between ER content and the gene expression of PACE4 has only been observed in 
human breast cancer [Cheng et al., 1997]; however, details of the correlation between 
the dynamic states of ER and PACE4 are still unclear.  Therefore, further studies are 
required to explain the mechanism underlying the transcriptional regulation of PACE4 
by estrogen stimuli, which was identified in this work.  Moreover, the substrate(s) 
leading to cell differentiation after activation by PACE4 in the presence of estrogen 
stimuli has not yet been identified in osteoblastic cells.  One candidate of interest is 
osteocalcin, an important marker for differentiated osteoblasts; its expression increased 
during the time course, similar to the expression of PACE4 at the late stage of cell 
differentiation (Fig. 6).  It is also known that osteocalcin requires cleavage at the SPC 
recognition motif (Table 1) in order to convert into the mature active form.  Therefore, 
further investigations are necessary to clarify the role of PACE4 in osteoblast 
differentiation. 
  In conclusion, the results from my present study strongly suggest that estrogen 
stimuli, including physiological estrogen and phytoestrogens such as Diz and Eq, 
induce osteoblast differentiation through upregulation of PACE4 mediated by the ER. 
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ABBREVATIONS 
 
ALP, alkaline phosphatase; BMPs, bone morphogenetic proteins 
CD-FBS, charcoal/dextran-treated FBS; ChM-1, chondromodulin-1 
Col-& , type & collagen; Col-' , type ' collagen; Col-( , type ( collagen 
Diz, daidzein; E2, 17%-estradiol; ER, estrogen receptor; Eq, equol 
FBS, fetal bovine serum; FGFR, fibroblast growth factor receptor 
Ful, fulvestrant; GFP, green fluorescent protein; GR, glucocorticoid receptors 
MSC, mesenchymal stem cell; PBS, phosphate-buffered saline 
RT-PCR, reverse transcription PCR; shRNA, short hairpin RNA 
SPC, subtilisin-like proprotein convertase; qRT-PCR, quantitative real-time PCR 
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